小剂量反应停联合化疗治疗多发性骨髓瘤的临床研究  

作　　者：张永峰[1] 杨雷[1] 马宁[1] 赵殿凤[1] 屈蓓蓓 韩庆坤[1] 刘子玲[1] 

机构地区：[1]吉林大学第一医院血液科,130021

出　　处：《中国社区医师（医学专业）》2008年第23期92-92,共1页

摘　　要：目的:探讨小剂量反应停联合化疗治疗多发性骨髓瘤(MM)的临床疗效。方法:治疗组小剂量反应停(50～200mg/日)联合化疗,对照组常规化疗,对其临床疗效进行对比分析。结果:治疗组nCR2例,PR10例,ORR60%;对照组nCR1例,PR8例,ORR30%。治疗组疗效优于对照组且具有统计学意义,治疗过程中无不能耐受的不良反应。结论:小剂量反应停增加化疗的疗效。Objectives：To approach the clinical effect of low dose thalidomide combind with chemotherapy in multiple myeloma （MM） treatment. Methods ： 20 patients with MM received the treatment of low dose thalidomide （50 - 200mg/d） which combined with the standard chemotherapy （VAD or MP） as the treatment group; 30 patients with MM received the treatment which only include the standard chemotherapy（VAD or MP） as the contradistinction group. Resuits：The ORR of the treatment group was 60% ,2 patients got nCR, 10 patients got PR;The ORR of the contradistinction group was30% ,1 patients got nCR,8 patients got PR. The treatment group was better than the contradistinction group, which possess the statistical significance. During the treatment all the patient could tolerant side effect. Conclusions：Low dose thalidomide combind with chemotherapy can be used as a better choice in multiple myeloma treatment.

关 键 词：多发性骨髓瘤 反应停 治疗 

分 类 号：R734.2[医药卫生—肿瘤] R733.3[医药卫生—临床医学]